Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COMMENTARY
A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council (Chuikyo). But opinions within the sector are divided over whether a formal seat on the country’s all-important reimbursement policymaking body…
To read the full story
Related Article
- Health Minister Mum on Legislation for Chuikyo Reform
September 2, 2026
- Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
- LDP, Ishin Seal Social Security Deal, Set Course for Chuikyo Reform
July 8, 2026
- Ishin Proposes Adding Drug, Device Makers to Chuikyo, LDP Wary
June 10, 2026
- LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
October 21, 2025
- Opposition Party Member Calls for Chuikyo Reform
January 27, 2025
COMMENTARY
- As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
September 7, 2026
- Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
September 3, 2026
- Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
August 25, 2026
- 9 Drugs Top 100 Billion Yen in FY2025 Japan Sales; Keytruda Retains Crown: Jiho Tally
August 20, 2026
- Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
August 3, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…